Wockhardt Files European Marketing Application for Novel Antibiotic WCK 5222 to Combat Drug-Resistant Infections
Key Insights
Wockhardt filed a Marketing Authorisation Application with the European Medicines Agency (search) on January 5, 2026, for WCK 5222, a novel antibiotic combining Zidebactam and Cefepime to treat resistant Gram-negative infections (search).
The European Medicines Agency (search) granted WCK 5222 Accelerated Assessment status, recognizing its potential to address unmet medical needs in treating multidrug-resistant and extremely drug-resistant Gram-negative pathogens.
WCK 5222 represents a landmark achievement as the first New Chemical Entity discovered and developed in India to be submitted for pan-European marketing authorisation.
Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (search) on January 5, 2026, for its novel antibiotic WCK 5222, marking a significant milestone in the fight against drug-resistant infections. The submission positions the Indian pharmaceutical company among a select group developing advanced solutions to combat life-threatening antimicrobial-resistant pathogens.
Accelerated Assessment Pathway
The European Medicines Agency (search) has granted WCK 5222 eligibility for Accelerated Assessment, a designation that shortens the standard review timeline for medicines of major public health importance. This status reflects the EMA's recognition that WCK 5222 has the potential to address an unmet medical need by providing an effective therapeutic option for serious and life-threatening infections.
The accelerated pathway underscores the urgency of making new and effective therapies available for patients suffering from multidrug-resistant bacterial infections, particularly those caused by multi-drug-resistant (MDR) and extremely drug resistant (XDR) Gram-negative pathogens.
Drug Composition and Target Indications
WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), designed specifically to treat resistant Gram-negative infections (search). These infections represent among the most serious challenges in modern medicine due to rising antimicrobial resistance and limited effective treatment options.
The proposed indications for WCK 5222 include:
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)
- Complicated intra-abdominal infections (cIAI)
- Treatment of patients with bacteraemia occurring in association with, or suspected to be associated with, cUTI/acute pyelonephritis, HAP/VAP, or cIAI
- Treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options
Regulatory Momentum Across Key Markets
In parallel with the European submission, the New Drug Application for WCK 5222 is under fast-track review by the US Food and Drug Administration (search). Priority review status in both Europe and the United States highlights strong regulatory momentum across key global markets.
The European Medicines Agency (search) is responsible for the scientific evaluation of new medicines across 27 European Union member states along with three European Economic Area countries—Norway, Iceland, and Liechtenstein—covering a total of 30 countries. Approval under this framework would enable WCK 5222 to be marketed across a large and strategically important healthcare region.
Historic Achievement for Indian Pharmaceutical Research
WCK 5222 represents a landmark achievement for Indian pharmaceutical research, being the first New Chemical Entity discovered and developed in India to be submitted for pan-European marketing authorisation. This milestone reflects the advancement of India-initiated global antimicrobial innovation efforts.
Wockhardt has stated that, based on the comprehensive clinical and regulatory data submitted, it expects approval of WCK 5222 for the treatment of resistant Gram-negative infections (search) across all countries under the EMA's jurisdiction. If approved, the drug could play a crucial role in addressing severe hospital-acquired infections and improving patient outcomes in critical care settings.